The company’s Emerald-3 study showed a 30% reduction in the risk of disease progression or death among embolization-eligible liver cancer patients who used an Imfinzi and Imjudo regimen. More: ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer Source:
read moreAlthough the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes. More: ASCO: Akeso’s ivonescimab bests PD-1 inhibitor
read moreIn its 2,000-patient Proteus study, J&J tested Erleada’s benefits when given to certain patients with prostate cancer before and after surgery. More: ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win Source: fierce
read moreThis year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year. But even as competitors swirl, RevMed is confident that it
read moreAfter winning a broader FDA label in metastatic castration-resistant prostate cancer, Pfizer’s combination of Talzenna and Xtandi is claiming a phase 3 win that positions it for a wider castration-sensitive patient population compared with J&J’s PARP doublet Akeega. More: ASCO:
read moreIn Lilly’s Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer. More: ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung
read more© 1994 - 2026 B.M. Pharmaceuticals